Ardsley Advisory Partners LP Cyma Bay Therapeutics, Inc. Transaction History

Ardsley Advisory Partners LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$1.33 - $5.93 $26,600 - $118,600	-20,000 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$6.05 - $13.66 $127,050 - $286,860	-21,000 Reduced 51.22%	20,000 $143,000
Q1 2019 May 15, 2019	BUY	$8.16 - $13.42 $8,160 - $13,420	1,000 Added 2.5%	41,000 $544,000
Q4 2018 Feb 14, 2019	SELL	$6.54 - $11.74 $65,400 - $117,400	-10,000 Reduced 20.0%	40,000 $315,000
Q2 2018 Aug 14, 2018	SELL	$10.66 - $14.38 $266,500 - $359,500	-25,000 Reduced 33.33%	50,000 $671,000
Q1 2018 May 15, 2018	SELL	$9.0 - $15.16 $3.83 Million - $6.44 Million	-425,000 Reduced 85.0%	75,000 $975,000
Q4 2017 Feb 14, 2018	BUY	$7.67 - $9.31 $3.3 Million - $4 Million	429,790 Added 612.15%	500,000 $4.6 Million
Q3 2017 Nov 14, 2017	BUY	$5.95 - $8.26 $119,000 - $165,200	20,000 Added 39.83%	70,210 $566,000
Q2 2017 Sep 21, 2017	BUY	N/A	50,210	50,210 $290,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Ardsley Advisory Partners LP, based on Form 13F filings with the SEC.

Stay updated on Ardsley Advisory Partners LP with notifications on news.